Plazomicin—a New Aminoglycoside—for Treating Complicated Urinary Tract Infections

Mohammad Saydur Rahman; Gazi Mohammad Al Amin; Shah Mohammad Anwar; Mohammad Ferdaus Azam; Fatema Akhter; Mohammad Rabiul Islam; Young-Sang Koh

doi:10.4167/jbv.2023.53.1.001

All Issue

2023 Vol.53, Issue 1 Next Page

Review Article

Plazomicin—a New Aminoglycoside—for Treating Complicated Urinary Tract Infections

30 June 2023. pp. 1-10

PDF XML

Abstract

Plazomicin belongs to a new class of semisynthetic aminoglycosides that suppress bacterial protein synthesis. The US Food and Drug Administration has approved this antibacterial drug for use in adult patients with complicated urinary tract infections (cUTIs), such as pyelonephritis. The worldwide emergence of multidrug- resistant (MDR) organisms has become a significant health issue. It is a promising alternative to carbapenems or β-lactam/β-lactamase inhibitors for treating cUTIs caused by MDR Enterobacterales. Plazomicin is primarily designed to overcome the common resistance mechanisms of pathogens. It has also demonstrated good in vitro efficacy against various resistant gram-negative pathogens. Plazomicin inhibits bacterial protein synthesis and exhibits rapid bactericidal efficacy against numerous extended-spectrum beta-lactamase (ESBL) producing, aminoglycoside- resistant, and carbapenem-resistant bacterial isolates. Similar to other aminoglycosides, plazomicin inhibits bacterial protein synthesis by attaching to the 30S ribosomal subunit of bacteria. Plazomicin also demonstrated a favorable minimum inhibitory concentration value compared to other aminoglycosides such as gentamicin, amikacin, and tobramycin. The commonly observed adverse effects of plazomicin include headache, hypertension, nausea, diarrhea, vomiting, and hypotension. In this review, we discuss the likelihood of using plazomicin to treat bacterial infections, focusing on its chemistry, mode of action pharmacokinetics, indications for treatment, adverse reactions, and safety profile.

Keywords

Plazomicin

Antibiotics

Aminoglycosides

References

Rahman MS, Koh YS. Omadacycline, a magic antibiotics for bacterial infections. J Bacteriol Virol 2018;48:109-12. 10.4167/jbv.2018.48.3.109

Clark JA, Burgess DS. Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance. Ther Adv Infect Dis 2020;7:2049936120952604. 10.1177/204993612095260432953108PMC7475792

Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SC, Rybak MJ. Teaching an old class new tricks: a novel semi-synthetic aminoglycoside, plazomicin. Infect Dis Ther 2019;8:155-70. 10.1007/s40121-019-0239-030850956PMC6522576

Bassetti M, Vena A, Castaldo N, Righi E, Peghin M. New antibiotics for ventilator-associated pneumonia. Curr Opin Infect Dis 2018;31:177-86. 10.1097/QCO.000000000000043829337703

Rahman MS, Koh YS. Delafloxacin, a new miracle in antibiotics armamentarium for bacterial infections. J Bacteriol Virol 2019;49:39-43. 10.4167/jbv.2019.49.1.39

Rahman MS, Koh YS. A novel antibiotic agent, cefiderocol, for multidrug-resistant Gram-negative bacteria. J Bacteriol Virol 2020;50:218-26. 10.4167/jbv.2020.50.4.218

Azam MF, Rahman MS, Al Amin GM, Miah MI, Koh YS. Delafloxacin, a superior antibacterial agent to its competitor fluoroquinolones. Korean J Microbiol 2021;57:133-41.

Sabih A, Leslie SW. Complicated urinary tract infections. In: StatPearls. Treasure Island: StatPearls Publishing, 2023.

Neal DE Jr. Complicated urinary tract infections. Urol Clin North Am 2008;35:13-22. 10.1016/j.ucl.2007.09.01018061020

Jindal J, Meelu A, Kaur S, Chahal HS, Makkar V, Garg V. Clinical profile and outcome in patients of complicated urinary tract infections: a single-center prospective observational study. Int J Appl Basic Med Res 2022;12:167-70. 10.4103/ijabmr.ijabmr_50_2236131855PMC9484510

Yan K, Liang B, Zhang G, Wang J, Zhu M, Cai Y. Efficacy and safety of plazomicin in the treatment of Enterobacterales infections: A meta-analysis of randomized controlled trials. Open Forum Infect Dis 2022;9:ofac429. 10.1093/ofid/ofac42936092826PMC9454024

Bilinskaya A, Linder KE, Kuti JL. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. Expert Rev Anti Infect Ther 2020;18:705-20. 10.1080/14787210.2020.175941932319833

López Díaz MC, Ríos E, Rodríguez-Avial I, Simaluiza RJ, Picazo JJ, Culebras E. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents. Int J Antimicrob Agents 2017;50:191-6. 10.1016/j.ijantimicag.2017.01.03928577932

Asempa TE, Avery LM, Kidd JM, Kuti JL, Nicolau DP. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm 2018;75:1048-56. 10.2146/ajhp17083929895521

Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med 2019;380:729-40. 10.1056/NEJMoa180146730786187

Asempa TE, Kuti JL, Seroogy JD, Komirenko AS, Nicolau DP. Application of the Hartford Hospital nomogram for plazomicin dosing interval selection in patients with complicated urinary tract infection. Antimicrob Agents Chemother 2019;63:e00148-19. 10.1128/AAC.00148-1931358580PMC6761540

Shaeer KM, Zmarlicka MT, Chahine EB, Piccicacco N, Cho JC. Plazomicin: a next-generation aminoglycoside. Pharmacotherapy 2019;39:77-93. 10.1002/phar.220330511766

Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012;10:459-73. 10.1586/eri.12.2522512755

Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM. Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections. Drugs 2019;79:243-69. 10.1007/s40265-019-1054-330723876

Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol 2010;13:565-73. 10.1016/j.mib.2010.09.00420932796

Karpiuk I, Tyski S. Looking for new preparations for antibacterial therapy. IV. New antimicrobial agents from the aminoglycoside, macrolide and tetracycline groups in clinical trials. Przegl Epidemiol 2015;69:723-9.

Syue LS, Chen YH, Ko WC, Hsueh PR. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Int J Antimicrob Agents 2016;47:250-8. 10.1016/j.ijantimicag.2015.12.02127005457

Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother 1999;43:727-37. 10.1128/AAC.43.4.72710103173PMC89199

Denervaud-Tendon V, Poirel L, Connolly LE, Krause KM, Nordmann P. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. J Antimicrob Chemother 2017;72:2787-91. 10.1093/jac/dkx23929091226

Houghton JL, Green KD, Chen W, Garneau‐Tsodikova S. The future of aminoglycosides: the end or renaissance? Chembiochem 2010;11:880-902. 10.1002/cbic.20090077920397253

Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin North Am 2016;30:523-37. 10.1016/j.idc.2016.02.01127208771PMC4878400

Ramirez MS, Tolmasky ME. Amikacin: uses, resistance, and prospects for inhibition. Molecules 2017;22:2267. 10.3390/molecules2212226729257114PMC5889950

Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. In vitro activity of plazomicin against Gram-negative and Gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant Enterobacteriaceae and isolates carrying carbapenemase genes. Antimicrob Agents Chemother 2018;62:e00313-18. 10.1128/AAC.00313-1829866862PMC6105795

Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother 2010;54:2258-61. 10.1128/AAC.01350-0920145088PMC2863652

Badal R, Lob S, Hackel M, Bouchillon S, Hoban D, Armstrong E. In vitro activity of ACHN-490 against recent respiratory tract pathogens. In: Proceedings of the 51st interscience conference on antimicrobial agents and chemotherapy. Chicago: ASM Press, 2011.

Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Zhanel GG. In vitro activity of plazomicin against gram-negative and gram-positive bacterial pathogens isolated from patients in Canadian hospitals from 2013 to 2017 as part of the CANWARD surveillance study. Antimicrob Agents Chemother 2018;63:e02068-18. 10.1128/AAC.02068-1830373806PMC6325181

Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53:4504-7. 10.1128/AAC.00556-0919770287PMC2764147

Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012;24:191-4. 10.1179/1973947812Y.000000001523040681PMC3401836

Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob Agents Chemother 2014;58:4443-51. 10.1128/AAC.00099-1424867988PMC4135979

Achaogen. Zemdri (plazomicin) injection, for intravenous use: US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303orig1s000lbl.pdf. Accessed 27 Jun 2018.

Biedenbach DJ., Badal RE, Huang MY, Motyl M, Singhal PK, Kozlov RS, et al. In vitro activity of oral antimicrobial agents against pathogens associated with community-acquired upper respiratory tract and urinary tract infections: a five country surveillance study. Infect Dis Ther 2016;5:139-53. 10.1007/s40121-016-0112-327287766PMC4929091

Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, et al. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 2010;54:4636-42. 10.1128/AAC.00572-1020805391PMC2976124

Saravolatz LD, Stein GE. Plazomicin: a new aminoglycoside. Clin Infect Dis 2020;70:704-9. 10.1093/cid/ciz64031328228

Clark JA, Kulengowski B, Burgess DS. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis 2020;98:115117. 10.1016/j.diagmicrobio.2020.11511732755805

García-Salguero C, Rodríguez-Avial I, Picazo JJ, Culebras E. Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii? Antimicrob Agents Chemother 2015;59:5959-66. 10.1128/AAC.00873-1526169398PMC4576036

Walterspiel JN, Feldman S, Van R, Ravis WR. Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactams and two beta-lactamase inhibitors, cilastatin and heparin. Antimicrob Agents Chemother 1991;35:1875-8. 10.1128/AAC.35.9.18751952861PMC245284

Serio AW, Keepers T, Krause KM. Plazomicin is active against metallo-β-lactamase-producing Enterobacteriaceae. Open Forum Infect Dis 2019;6:ofz123. 10.1093/ofid/ofz12330968059PMC6446133

Thwaites M, Hall D, Shinabarger D, Serio AW, Krause KM, Marra A, et al. Evaluation of the bactericidal activity of plazomicin and comparators against multidrug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2018;62:e00236-18. 10.1128/AAC.00236-1829866876PMC6105851

Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 2017;62:e01904-17. 10.1128/AAC.01904-1729084745PMC5740317

Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015-2016. Diagn Microbiol Infect Dis 2018;92:69-74. 10.1016/j.diagmicrobio.2018.04.01229789189

Noel AR, Attwood M, Bowker KE, Kim A, Krause KM, MacGowan AP. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection. Int J Antimicrob Agents 2019;54:626-32. 10.1016/j.ijantimicag.2019.07.00131299297

Cass RT, Brooks CD, Havrilla NA, Tack KJ, Borin MT, Young D, et al. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother 2011;55:5874-80. 10.1128/AAC.00624-1121911572PMC3232771

Trang M, Seroogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, et al. Population pharmacokinetic analyses for plazomicin using pooled data from phase 1, 2, and 3 clinical studies. Antimicrob Agents Chemother 2019;63: e02329-18. 10.1128/AAC.02329-1830670433PMC6496156

Karaiskos I, Souli M, Giamarellou H. Plazomicin: an investigational therapy for the treatment of urinary tract infections. Expert Opin Investig Drugs 2015;24:1501-11. 10.1517/13543784.2015.109518026419762

Komirenko AS, Riddle V, Gibbons JA, Van Wart S, Seroogy JD. A phase 1 study to assess the pharmacokinetics of intravenous plazomicin in adult subjects with varying degrees of renal function. Antimicrob Agents Chemother 2018;62:e01128-18. 10.1128/AAC.01128-1830275092PMC6256775

Bhavnani S, Hammel J, Trang M, Kim A, Krause K, Castanheira M. Pharmacokinetic-pharmacodynamic target attainment analyses to support plazomicin dose selection and recommendations for interpretive criteria for in vitro susceptibility testing for Enterobacteriaceae. In: Proceedings of ASM Microbe 2018. Atlanta: ASM Press, 2018.

Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrob Agents Chemother 2018;62:e01989-17. 10.1128/AAC.01989-1729378708PMC5913993

Abdelraouf K, Kim A, Krause KM, Nicolau DP. In vivo efficacy of plazomicin alone or in combination with meropenem or tigecycline against Enterobacteriaceae isolates exhibiting various resistance mechanisms in an immunocompetent murine septicemia model. Antimicrob Agents Chemother 2018;62:e01074-18. 10.1128/AAC.01074-1829866866PMC6105799

Baudou E, Lespine A, Durrieu G, André F, Gandia P, Durand C, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med 2020;383:787-9. 10.1056/NEJMc191734432813957

Information

Publisher :The Korean Society for Microbiology and The Korean Society of Virology
Publisher(Ko) :대한미생물학회‧대한바이러스학회
Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
Volume : 53
No :1
Pages :1-10
Received Date : 2023-05-09
Revised Date : 2023-06-21
Accepted Date : 2023-06-23
DOI :https://doi.org/10.4167/jbv.2023.53.1.001

JOURNAL OF BACTERIOLOGY AND VIROLOGY ISSN:1598-2467(Print) 2093-0429(Online)

All Issue